Death from all causes during treatment (range 6 days to 16 days) · acute ischaemic stroke
Low‐molecular‐weight heparins or heparinoids showed no clear difference in death from all causes during treatment (range 6 days to 16 days) compared with unfractionated heparin (low certainty).
1 finding from 1 review
Death from all causes during · acute ischaemic stroke
Low‐molecular‐weight heparins or heparinoids showed no clear difference in death from all causes during compared with unfractionated heparin (low certainty).
1 finding from 1 review
Deep vein thrombosis · acute ischaemic stroke
Low‐molecular‐weight heparins or heparinoids may leads to lower deep vein thrombosis during treatment period (range 6 days to 16 days) compared with unfractionated heparin (low certainty).
1 finding from 1 review
Pulmonary embolism · acute ischaemic stroke
Low‐molecular‐weight heparins or heparinoids showed no clear difference in pulmonary embolism during treatment period (range 6 days to 16 days) compared with unfractionated heparin (low certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage/haemorrhagic transformation of the cerebral infarct during treatment period (range 6 days to 16 days)⁹ · acute ischaemic stroke
Low‐molecular‐weight heparins or heparinoids showed no clear difference in symptomatic intracranial haemorrhage/haemorrhagic transformation of… compared with unfractionated heparin (low certainty).
1 finding from 1 review
PE: assessed by CT arteriography ( · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in PE: assessed by CT arteriography ( compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in symptomatic DVT: assessed by presence of symptoms and confirmed by a… compared with no prophylaxis (low certainty).
1 finding from 1 review
Asymptomatic DVT · adults undergoing KA
It is very uncertain whether low‐molecular‐weight heparin changes asymptomatic DVT: compared with no prophylaxis (very low certainty).
1 finding from 1 review
All‐cause mortality ( · adults undergoing KA
1 finding from 1 review
All adverse effects, including allergies at injection site, minor and major bleeding, others ( · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in major bleeding ( compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · adults undergoing KA
Low‐molecular‐weight heparin showed no clear difference in minor bleeding ( compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to lower symptomatic PE compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower any VTE compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with no thromboprophylaxis (low certainty).
1 finding from 1 review
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to higher clinically relevant bleeding compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in symptomatic VTE compared with with active control (1) (low certainty).
3 findings from 1 review
RR 2.89 [0.12, 66.75]
1 study · 51 participants
Low
RR 0.51 [0.22, 1.17]
2 studies · 781 participants
Moderate
RR 0.33 [0.14, 0.83]
1 study · 439 participants
High
Major bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with with active control (1); GRADE not reported.
3 findings from 1 review